• Flanders Investment & Trade
  • Team Vesalius
Team Vesalius

Tim Van Hauwermeiren

Bio-engineer Tim Van Hauwermeiren co-founded biotech company Argen-X in 2008, together with Hans de Haard and Torsten Dreier.

Tim Van Hauwermeiren

Argen-X

CEO
Industriepark Zwijnaarde 7
9052 Ghent
Belgium

Until that time, he was senior business development executive at Ablynx. Prior to joining Ablynx, Van Hauwermeiren held various management positions with the Procter & Gamble Company in R&D and corporate new business development, where he conceived and developed several new products.

He was awarded the 2000 F&HC New Business Development Award for Outstanding Courage and Commitment and was nominated for the John Smale Innovation Award in 2001. As a chairman, Van Hauwermeiren holds positions in Aelin Therapeutics and iTeos Pharmaceuticals.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?